FDA Approves Wider Use Visudyne

Article

QLT, Inc. and Ciba Vision Corporation have been given priority-review status from the Food and Drug Administration (FDA) for their application to expand therapy involving their blindness drug Visudyne to treatment of a range of eye diseases. Among other things, the companies are seeking permission to use Visudyne to treat certain conditions that can cause blindness in younger people. Currently, the two companies have US marketing approval for its use to treat only certain forms of age-related macular degeneration, the leading cause of blindness in people over 50 years old. For more information, visit www.fda.org.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
Jill Holdsworth, MS, CIC, FAPIC, NREMT, CRCST, CHL, an infection preventionist from Atlanta, Georgia.  (Photo credit: Tori Whitacre Martonicz)
"Top 5" in a blue ribbon  (Adobe Stock 235182652 by Evgeny)
Bug of the Month
© 2025 MJH Life Sciences

All rights reserved.